文献速递泌尿男性生殖肿瘤

深度学习系统用于前列腺穿刺活检Gleason分级的开发与验证

Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究评估深度学习系统(DLS)对前列腺穿刺活检标本进行Gleason分级的能力,使用来自美国3家机构的752张数字化图像,以亚专科专家的多数意见为参考标准。在含肿瘤的498例标本中,DLS与专家意见的完全一致率(71.7%)显著高于19名普通病理学家(58.0%),且在外部验证集(n=322)中性能相似;区分肿瘤与非肿瘤的准确率两者相近。

要点

  • DLS对含肿瘤穿刺标本的Gleason分级与专家一致率71.7%,高于普通病理学家的58.0%。
  • 在外部机构验证集中DLS的Gleason分级性能保持相似。
  • 区分肿瘤与非肿瘤时DLS与普通病理学家一致率相近(94.3% vs 94.7%)。

核心结论

  • DLS在前列腺穿刺活检Gleason分级上优于普通病理学家,并可推广至独立机构。

研究设计与样本

  • 使用来自美国3家机构的752张数字化前列腺穿刺活检图像评估DLS,其中1家机构未用于DLS开发。
  • 以6名泌尿亚专科专家(平均经验25年,范围18-34年)中2人初审、第三人复核分歧后的多数意见为参考标准。
  • 比较19名普通病理学家与专家多数意见的一致率。

主要发现

  • 在含肿瘤的498例验证集标本中,DLS与专家一致率为71.7%(95%CI,67.9%-75.3%),普通病理学家为58.0%(95%CI,54.5%-61.4%),P < .001。
  • 在外部验证集的322例标本中,DLS的Gleason分级性能保持相似。
  • 在区分非肿瘤与含肿瘤的752例标本中,DLS一致率为94.3%(95%CI,92.4%-95.9%),普通病理学家为94.7%(95%CI,92.8%-96.3%),P = .58。

临床怎么用

  • DLS有望作为决策支持工具用于临床工作流程,以提高前列腺癌分级的质量。

局限性

  • 需进一步研究评估DLS作为决策支持工具在临床工作流程中的潜在效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For prostate cancer, Gleason grading of the biopsy specimen plays a pivotal role in determining case management. However, Gleason grading is associated with substantial interobserver variability, resulting in a need for decision support tools to improve the reproducibility of Gleason grading in routine clinical practice. OBJECTIVE: To evaluate the ability of a deep learning system (DLS) to grade diagnostic prostate biopsy specimens. DESIGN, SETTING, AND PARTICIPANTS: The DLS was evaluated using 752 deidentified digitized images of formalin-fixed paraffin-embedded prostate needle core biopsy specimens obtained from 3 institutions in the United States, including 1 institution not used for DLS development. To obtain the Gleason grade group (GG), each specimen was first reviewed by 2 expert urologic subspecialists from a multi-institutional panel of 6 individuals (years of experience: mean, 25 years; range, 18-34 years). A third subspecialist reviewed discordant cases to arrive at a majority opinion. To reduce diagnostic uncertainty, all subspecialists had access to an immunohistochemical-stained section and 3 histologic sections for every biopsied specimen. Their review was conducted from December 2018 to June 2019. MAIN OUTCOMES AND MEASURES: The frequency of the exact agreement of the DLS with the majority opinion of the subspecialists in categorizing each tumor-containing specimen as 1 of 5 categories: nontumor, GG1, GG2, GG3, or GG4-5. For comparison, the rate of agreement of 19 general pathologists' opinions with the subspecialists' majority opinions was also evaluated. RESULTS: For grading tumor-containing biopsy specimens in the validation set (n = 498), the rate of agreement with subspecialists was significantly higher for the DLS (71.7%; 95% CI, 67.9%-75.3%) than for general pathologists (58.0%; 95% CI, 54.5%-61.4%) (P < .001). In subanalyses of biopsy specimens from an external validation set (n = 322), the Gleason grading performance of the DLS remained similar. For distinguishing nontumor from tumor-containing biopsy specimens (n = 752), the rate of agreement with subspecialists was 94.3% (95% CI, 92.4%-95.9%) for the DLS and similar at 94.7% (95% CI, 92.8%-96.3%) for general pathologists (P = .58). CONCLUSIONS AND RELEVANCE: In this study, the DLS showed higher proficiency than general pathologists at Gleason grading prostate needle core biopsy specimens and generalized to an independent institution. Future research is necessary to evaluate the potential utility of using the DLS as a decision support tool in clinical workflows and to improve the quality of prostate cancer grading for therapy decisions.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Nagpal K, Foote D, Tan F, et al. Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. JAMA Oncol. 2020. PMID: 32701148. doi:10.1001/jamaoncol.2020.2485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。